NRx Pharmaceuticals (NASDAQ:NRXP) Receives “Buy” Rating from D. Boral Capital

NRx Pharmaceuticals (NASDAQ:NRXP)‘s stock had its “buy” rating reaffirmed by equities researchers at D. Boral Capital in a report released on Tuesday,Benzinga reports. They presently have a $34.00 price target on the stock.

Several other analysts have also recently weighed in on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of NRx Pharmaceuticals in a research report on Monday, December 29th. BTIG Research reissued a “buy” rating and issued a $25.00 target price on shares of NRx Pharmaceuticals in a research note on Tuesday. Ascendiant Capital Markets restated a “buy” rating and set a $48.00 price target (up from $47.00) on shares of NRx Pharmaceuticals in a research report on Friday, January 2nd. HC Wainwright lifted their price target on NRx Pharmaceuticals from $40.00 to $45.00 and gave the stock a “buy” rating in a research note on Tuesday, March 3rd. Finally, Zacks Research upgraded NRx Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Monday, March 2nd. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, NRx Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $38.00.

NRx Pharmaceuticals Stock Up 17.8%

Shares of NRXP stock traded up $0.32 during trading on Tuesday, hitting $2.09. The company had a trading volume of 1,164,907 shares, compared to its average volume of 1,054,915. The stock’s 50-day moving average is $1.94 and its two-hundred day moving average is $2.44. The stock has a market capitalization of $66.45 million, a price-to-earnings ratio of -0.89 and a beta of 1.97. NRx Pharmaceuticals has a 52 week low of $1.58 and a 52 week high of $3.84.

NRx Pharmaceuticals (NASDAQ:NRXP) last announced its earnings results on Monday, March 23rd. The company reported $0.19 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.28. The company had revenue of $0.98 million for the quarter, compared to the consensus estimate of $7.53 million. On average, research analysts predict that NRx Pharmaceuticals will post -1.75 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Ethos Financial Group LLC bought a new position in NRx Pharmaceuticals during the 3rd quarter worth approximately $39,000. Sjbenen Advisory LLC bought a new stake in NRx Pharmaceuticals during the 4th quarter valued at $41,000. One Wealth Management Investment & Advisory Services LLC boosted its position in NRx Pharmaceuticals by 86.1% during the 3rd quarter. One Wealth Management Investment & Advisory Services LLC now owns 27,991 shares of the company’s stock valued at $92,000 after buying an additional 12,950 shares during the period. Global Retirement Partners LLC bought a new stake in NRx Pharmaceuticals in the 4th quarter worth $107,000. Finally, Two Sigma Investments LP grew its holdings in NRx Pharmaceuticals by 66.4% in the 3rd quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock worth $173,000 after acquiring an additional 20,880 shares during the last quarter. Hedge funds and other institutional investors own 4.27% of the company’s stock.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.